肝移植术后针对肝癌复发的免疫抑制药物优化
Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.
作者信息
Khorsandi Shirin Elizabeth, Heaton Nigel
机构信息
Institute of Liver Studies, King's Healthcare Partners at Denmark Hill, King's College Hospital NHSFT, London, SE5 9RS, UK.
出版信息
Transl Gastroenterol Hepatol. 2016 Apr 6;1:25. doi: 10.21037/tgh.2016.03.18. eCollection 2016.
Abstract
The introduction of liver transplant listing criteria for hepatocellular cancer (HCC) has significantly improved oncological outcomes and survival. But despite this HCC recurrence is still problematic. There is emerging evidence that the choice of immunosuppression (IS) after transplant for HCC can influence oncological survival and HCC recurrence. The following is a short summary of what has been published on HCC recurrence with the different classes of immunosuppressive agents in present use, concluding with the possible rationalization of the use of these immunosuppressive agents in the post-transplant patient at high risk of recurrence.
摘要
肝细胞癌（HCC）肝移植列入标准的引入显著改善了肿瘤学结局和生存率。但尽管如此，HCC复发仍然是个问题。越来越多的证据表明，HCC移植后免疫抑制（IS）的选择会影响肿瘤学生存率和HCC复发。以下是关于目前使用的不同类别的免疫抑制剂与HCC复发相关已发表内容的简短总结，最后讨论在复发高危的移植后患者中使用这些免疫抑制剂的可能合理性。
相似文献
1
Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.肝移植术后针对肝癌复发的免疫抑制药物优化
Transl Gastroenterol Hepatol. 2016 Apr 6;1:25. doi: 10.21037/tgh.2016.03.18. eCollection 2016.
2
Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.影响肝细胞癌肝移植生存因素的研究：来自布达佩斯的单中心经验
Transplant Proc. 2015 Sep;47(7):2201-6. doi: 10.1016/j.transproceed.2015.07.026.
3
Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.肝移植后复发风险高的肝细胞癌患者基于依维莫司的免疫抑制：病例系列
Transplant Proc. 2014 Dec;46(10):3496-501. doi: 10.1016/j.transproceed.2014.08.045.
4
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.高危复发性肝细胞癌的预防性肝移植
World J Hepatol. 2016 Nov 8;8(31):1309-1317. doi: 10.4254/wjh.v8.i31.1309.
5
Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation.肝移植后感染可改善原位肝移植后肝细胞癌患者的预后。
World J Gastroenterol. 2019 Oct 7;25(37):5630-5640. doi: 10.3748/wjg.v25.i37.5630.
6
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.肝移植后复发性肝细胞癌患者的多模态肿瘤学方法。
Eur Rev Med Pharmacol Sci. 2017 Aug;21(15):3421-3435.
7
Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.西罗莫司维持性免疫抑制在肝癌肝移植后的作用
Liver Transpl. 2016 May;22(5):627-34. doi: 10.1002/lt.24395.
8
Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.系统评价与荟萃分析：肝移植治疗肝细胞癌后使用西罗莫司或依维莫司为基础的免疫抑制治疗。
Aliment Pharmacol Ther. 2019 May;49(10):1260-1273. doi: 10.1111/apt.15253. Epub 2019 Apr 15.
9
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.西罗莫司为基础的免疫抑制治疗与肝癌肝移植术后患者的生存获益相关。
Hepatology. 2010 Apr;51(4):1237-43. doi: 10.1002/hep.23437.
10
Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.雷帕霉素哺乳动物靶点抑制剂与肝移植后肝细胞癌复发率较低相关：一项系统评价
Transpl Int. 2014 Oct;27(10):1039-49. doi: 10.1111/tri.12372. Epub 2014 Jul 18.
引用本文的文献
1
Circular RNA circ_KIAA1429 accelerates hepatocellular carcinoma progression via the miR-133a-3p/high mobility group AT-hook 2 (HMGA2) axis in an m6A-dependent manner.环状 RNA circ_KIAA1429 通过 m6A 依赖性方式经由 miR-133a-3p/高迁移率族 AT 钩状结构域 2 (HMGA2) 轴促进肝细胞癌进展。
Hum Cell. 2023 Sep;36(5):1741-1754. doi: 10.1007/s13577-023-00933-3. Epub 2023 Jun 27.
2
The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma.mTOR 抑制剂在肝癌肝移植术后的作用。
Curr Oncol. 2023 Jun 9;30(6):5574-5592. doi: 10.3390/curroncol30060421.
3
Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes.基于色氨酸代谢相关基因预测肝细胞癌预后及免疫治疗效果
Cancer Cell Int. 2022 Oct 10;22(1):308. doi: 10.1186/s12935-022-02730-8.
4
[CDK1, CCNB1 and NDC80 are associated with prognosis and progression of hepatitis B virus-associated hepatocellular carcinoma: a bioinformatic analysis].[细胞周期蛋白依赖性激酶1、细胞周期蛋白B1和NDC80与乙型肝炎病毒相关肝细胞癌的预后和进展相关：一项生物信息学分析]
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Oct 20;41(10):1509-1518. doi: 10.12122/j.issn.1673-4254.2021.10.09.
5
Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation.实现肝细胞癌完全缓解：肝移植后无复发生存的重要预测因素。
Can J Gastroenterol Hepatol. 2019 Jan 8;2019:5796074. doi: 10.1155/2019/5796074. eCollection 2019.
6
Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis.美国肝移植维持免疫抑制治疗中以中心为导向和以临床为导向的差异：一项全国性实践模式分析。
Transplant Direct. 2018 Jun 13;4(7):e364. doi: 10.1097/TXD.0000000000000800. eCollection 2018 Jul.
本文引用的文献
1
Does Donation After Cardiac Death Utilization Adversely Affect Hepatocellular Cancer Survival?心脏死亡后器官捐献的使用是否会对肝细胞癌患者的生存产生不利影响？
Transplantation. 2016 Sep;100(9):1916-24. doi: 10.1097/TP.0000000000001150.
2
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.西罗莫司在肝细胞癌肝移植受者中的应用：一项随机、多中心、开放标签的3期试验。
Transplantation. 2016 Jan;100(1):116-25. doi: 10.1097/TP.0000000000000965.
3
The Use of Donation After Cardiac Death Allografts Does Not Increase Recurrence of Hepatocellular Carcinoma.使用心跳停止供体移植物不会增加肝细胞癌的复发。
Am J Transplant. 2015 Oct;15(10):2704-11. doi: 10.1111/ajt.13306. Epub 2015 May 12.
4
Hepatocellular carcinoma epidemiology.肝细胞癌流行病学
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):753-70. doi: 10.1016/j.bpg.2014.08.007. Epub 2014 Aug 23.
5
Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma.辅助性索拉非尼在高危肝细胞癌肝移植受者中的应用。
J Transplant. 2014;2014:913634. doi: 10.1155/2014/913634. Epub 2014 Apr 10.
6
Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis.肝移植治疗肝细胞癌：炎症和免疫状态对复发和预后的作用。
World J Gastroenterol. 2013 Dec 28;19(48):9174-82. doi: 10.3748/wjg.v19.i48.9174.
7
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.肝移植术后肝细胞癌患者个性化免疫抑制药物治疗的原理
Liver Transpl. 2014 Mar;20(3):261-9. doi: 10.1002/lt.23806. Epub 2014 Jan 27.
8
Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes.他克莫司、硫唑嘌呤和类固醇治疗复发性 HCV 时纤维化减少与他克莫司：随机试验长期结果。
Gut. 2014 Jun;63(6):1005-13. doi: 10.1136/gutjnl-2013-305606. Epub 2013 Oct 16.
9
How much immunosuppression is needed after liver transplantation?肝移植后需要多少免疫抑制？
Clin Transplant. 2014 Jan;28(1):6-7. doi: 10.1111/ctr.12242. Epub 2013 Sep 13.
10
Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma.肝移植患者肝癌患者应用无类固醇免疫抑制与标准免疫抑制的比较。
PLoS One. 2013 Aug 6;8(8):e71251. doi: 10.1371/journal.pone.0071251. Print 2013.
Zotero 插件